FolioLanternBeta
ORKAOruka Therapeutics, Inc.

Paul Quinlan

General Counsel at Oruka Therapeutics, Inc., as of Sep 21, 2026Sold $6.8M of stock in the past 12 months: 97% under a disclosed plan and 3% to cover taxes.

Updated Oct 15, 2026 from SEC filings · covers Oct 16, 2025 to Oct 15, 2026
68%†
share of stake sold at Oruka Therapeutics, Inc.
† Measured against shares held at the start plus shares received, because most of the shares sold arrived during the period.
30K
shares held after the latest filing, Oruka Therapeutics, Inc.
Vested shares reported on Forms 3, 4 and 5 only. Not the insider's whole wealth.
1
company filed for

Selling by month

Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesOne dollar scale for every month; the tallest bar is labeled
OctNovDecJanFebMar 2026: $30K to cover taxesMarAprMayJun 2026: $51K to cover taxesJunJulAug 2026: $5.6M under a disclosed plan$5.6MAugSep 2026: $936K under a disclosed planSep 2026: $99K to cover taxesSepOct

Pattern

What the filings show, past 12 months. Nothing here rates or predicts.

Roles from filings

Every company we track where this person has filed, newest filing first.

CompanyTitleFirst filingLatest filing
Oruka Therapeutics, Inc. (ORKA)General CounselSep 6, 2024Sep 21, 2026

Recent filings

The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.

This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.